Distribution of Menaquinone-4, a Therapeutic Agent for Osteoporosis, in Bone and Other Tissues of Rats.

スポンサーリンク

概要

• 論文の詳細を見る

• [14C] Menaquinone-4 was administered orally once daily at a dose of 4 mg/kg for ten days to female rats of different ages to determine its blood and tissue distribution with particular attention to its distribu-tion in bone. Animals aged 10 and 30 months were either ovariectomized or sham-operated as a control, and young rats aged 7 weeks were used as untreated controls. Blood concentrations of radioactivity at 24h after each dose during repeated administration increased daily and approached a steady state byy the seventh dose. Higher concentrations of radioactivity in blood (plasma) were observed in older animals than in the younger ones, but there was little difference between ovariectomized rats (OVX rats) and sham-operated rats (Sham rats). In tissue samples collected at 1.5h after administration, the liver, adipose tissue, spleen and adrenals showed higher concentrations of radioactivity than the other organs and the plasma. In bone tissues, the bone marrow (BM) and cancellous tissue (CT) of the femur showed radioactivity concentrations which were higher than that in the plasma, and these increased during repeated administration. Finally, at 24h after the last dose, the concentrations of radioactivity in bone tissues of older animals (BM, 5, 807.2ng eq/g; CT, 5, 264.8ng eq/g in OVX rats aged 10 months and BM, 11, 479.3ng eq/g; CT, 4, 023.0ng eq/g in OVX rats aged 30 months) were several times higher than those in younger animals (BM, 2, 771.6ng eq/g; CT, 890.2ng eq/g in 7-week-old untreated rats). The values in OVX rats were also higher than those in Sham rats. Furthermore, micro autoradiography studies of femur sections from OVX rats indicated that [14C] Menaqui-none-4 localized in cancellous tissue where bone is known to be actively remodelled. The concentrations of radioactivity in cancellous tissue and bone marrow of OVX rats aged 10 and 30 months were comparable to the pharmacologically effective concentrations of Menaquinone-4 (10-6-10-5 M) in in vitro studies on bone formation. These findings suggest that orally administered Menaquinone-4 distributes specifically into the bone tissues of ovariectomized rats and this is consistent with its effect as a therapeutic agent for osteoporosis.

• 財団法人 学会誌刊行センターの論文

著者

• SANO Yoshihisa

  Tsukuba Research Laboratories, Eisai Co., Ltd.

• KIKUCHI Kiyomi

  Tsukuba Research Laboratories, Eisai Co., Ltd.

• KANEKO Kazuhiro

  Tsukuba Research Laboratories, Eisai Co., Ltd.

• Yuzuriha Teruaki

  Tsukuba Research Laboratories Eisai Co. Ltd.

• Kikuchi Kiyomi

  Tsukuba Research Laboratories Eisai Co. Ltd.

• Kaneko Kazuhiro

  Tsukuba Research Laboratories Eisai Co. Ltd.

• TADANO Kyolchi

  Tsukuba Research Laboratories, Eisai Co., Ltd.

• SANO Yoshihisa

  Tsukuba Research Laboratories, Eisai Co. Ltd

関連論文

• Metabolic Fate of Menaquinone-4 in Dogs (II): Absorption, Distribution, Metabolism and Excretion after Repeated Oral Administration
• Metabolic Fate of Menaquinone-4 in Dogs (I): Absorption, Distribution, Metabolism and Excretion after a Single Oral Administration
• IDENTIFICATION OF MENAQUINONE-4 METABOLITES IN THE RAT
• Simultaneous Determination of Menaquinone-4 and Its Metabolite in Human Osteoblasts by High-Performance Liquid Chromatography / Atmospheric Pressure Chemical Ionization Tandem Mass Spectrometry
• EFFECT OF SOLUBILIZER ON THE METABOLIC FATE OF MENAQUINONE-4 IN RATS
• Sodium ferrous citrate does not cause aluminum retention in rats with experimentally induced renal failure
• Pharmacokinetic Characterization of Menaquinone-4 in Dogs by Sensitive HPLC Determination.
• Distribution of Menaquinone-4, a Therapeutic Agent for Osteoporosis, in Bone and Other Tissues of Rats.
• Thrombolysis of Canine Femoral Artery Thrombus by a Novel Modified Tissue-Type Plasminogen Activator (E6010).

スポンサーリンク